Introduction {#sec1-1}
============

Acute Ischemic Stroke is the leading cause of neurologic disability in adults; 200,000 deaths annually in the United States. Much can be done to limit morbidity and mortality through prevention and acute intervention. Stroke patients have sudden neurologic deficit due to vascular mechanism that is ischemic in 85% or primary hemorrhages 15% (subarachnoid or intraparenchymal). An ischemic deficit that resolves rapidly (24 h) is termed a *transient ischemic attack* (TIA). Stroke disease causes cognitive damage worsening the quality of life of the hospetalized patients: decline of praxis capacities, time-space orientation, swallowing ([@ref1], [@ref2]) and quality of life. Our observation shows the effect of low dose of Rotigotine patches (a complete dopamine agonist D3\>D2\>D1) on cognitive impairment ([@ref3]) in 19 elderly patients with acute ischemic stroke. We used a trandermal dopaminergic therapy for the low compliance to oral therapy and the frequent presence of liver and kidney failure. Some recent data in literature underline that rotigotine could improve the cognitive impairment ([@ref4]) and swallowing.

Materials and methods {#sec1-2}
=====================

A total of 19 patients are observed from july 1, 2016, through December 17, 2016. All patients fulfil the criteria for the study. No patients underwent randomization erroneously or were enrolled at sites that were closed owing to serious Good Clinical Practice violations. Most patients received recommended pharmacologic therapy for hypertension disease. Elegibility requirements at screening included age of at least 18 yrs. Our observation is caratherized by a run-in period (24 hours after the admission to the Internal Medicine Department) during wich all patients received rotigotine 2 mg/24h transdermal patch after a basal tests evaluation. After 24 hours no patient showed side effects due to dopaminergic therapy and therefore are underwent to follow up. We have treated 19 patients (10 male and 9 female with range age 70-92 yrs) with recent acute ischemic stroke wich determined hemiparesis or hemiplegia associated to a decline of praxis capacities, time-space orientation and swallowing ([@ref3]), with high cardiovascular risk profile in 90% of cases. It was evaluated the adherence to therapy and the cognitive function using MMSE test, Morinsky Scale and swallowing test (acts/minute) before and post-administration of Rotigotine 2 mg/24h. Patients were subjected to multi-parametric evaluation. Data were collected, managed, and analyzed for statistical analysis using Sigmastat Analysis Program (version 3.5). Statistical analysis was performed with Wilcoxon singed rank test to compare data in small group. Sigmastat Analysis Program (version 3.5) is also used for graphic representation.

All the patients provided written informed consent.
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Results {#sec1-3}
=======

We obteined a statistical evaluation on all enrolled patients with cognitive impairment due to acute ischemic stroke after 7 days of treatment with Rotigotine 2 mg/24h transdermal patch. At the end of the treatment, tha data have showed a statistically significant correlation about improvement of MMSE test ([@ref6]-[@ref8]) swallowing test and Morinsky scale from a basal value. Further evaluation are needed to have conclusive results.

Conclusion {#sec1-4}
==========

Rotigotine could be a new useful approach in the treatment of elderly hospetalized patients with recent stroke correlated with cognitive impairment, expecially about praxis capacities, time-space orientation and swallowing. This observation led us to use rotigotine transdermal patches 2 mg/24 h in patients with cognitive degeneration related to acute ischemic stroke ([@ref5])treated in Internal Medicine Department. Rotigotine was effective and well-tolerated when used in routine clinical practice. Our data give comfortable results but further evaluation are needed to have conclusive results.
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